
Linda Yaccarino’s subsequent position after departing X as CEO can be one other chief government position at eMed Population Health, an AI startup constructing a tech platform for sufferers utilizing GLP-1s.
Yaccarino was a longtime promoting government at NBCUniversal however left to hitch X as CEO for 2 years, the place she managed to have a positive impact on the social community’s troubled advert income mannequin, regardless of her and Elon Musk’s shared strategy to minimizing content material moderation.
Although Yaccarino doesn’t have expertise in well being tech, eMed mentioned in a press launch that they sought her out for her “simple means to barter new partnerships” — it definitely additionally helps that her tenure at X made her well-known within the tech world, drawing extra eyes towards the startup.
eMed previously produced a tech platform that was designed for use with at-home COVID-19 fast antigen assessments, guiding customers via the method of administering these assessments correctly. Now eMed is targeted on GLP-1s, the category of medication like Ozempic, which can be utilized for each weight administration and remedy of kind 2 diabetes.
“To be a frontrunner in right now’s healthcare market, firms must have a fearless tenacity that enables them to not solely develop, however to even be courageous sufficient to step ahead and redefine a whole trade,” Yaccarino said in a press launch. “We’re very well-positioned to be that tenacious chief, striving towards our final purpose of enhancing international healthcare outcomes via our groundbreaking providers and platforms.”
Trending Merchandise

